Results 81 to 90 of about 4,640 (210)

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

New England Journal of Medicine, 2019
BACKGROUND Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, inhibits nuclear factor κB, and reduces oncoprotein messenger RNA ...
A. Chari, D. Vogl, M. Gavriatopoulou, A. Nooka, Andrew J. Yee, C. Huff, P. Moreau, D. Dingli, Craig E. Cole, S. Lonial, M. Dimopoulos, A. Stewart, J. Richter, R. Vij, S. Tuchman, M. Raab, K. Weisel, M. Delforge, R. Cornell, D. Kaminetzky, J. Hoffman, Luciano J. Costa, Terri L. Parker, M. Levy, M. Schreder, N. Meuleman, L. Frenzel, M. Mohty, S. Choquet, G. Schiller, R. Comenzo, M. Engelhardt, T. Illmer, P. Vlummens, C. Doyen, T. Facon, Lionel Karlin, A. Perrot, K. Podar, M. Kauffman, S. Shacham, Lingling Li, Shijie Tang, Carla Picklesimer, J. Saint-Martin, Marsha L. Crochiere, Hua Chang, S. Parekh, Y. Landesman, J. Shah, Paul G. Richardson, S. Jagannath   +51 more
semanticscholar   +1 more source

A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

Journal of Hematology & Oncology, 2018
Background Novel therapies for patients with acute myeloid leukemia (AML) are imperative, particularly for those with high-risk features. Selinexor, an exportin 1 (XPO1/CRM1) inhibitor, has demonstrated anti-leukemia activity as a single agent, as well ...
Amy Y. Wang, Howard Weiner, Margaret Green, Hua Chang, Noreen Fulton, Richard A. Larson, Olatoyosi Odenike, Andrew S. Artz, Michael R. Bishop, Lucy A. Godley, Michael J. Thirman, Satyajit Kosuri, Jane E. Churpek, Emily Curran, Kristen Pettit, Wendy Stock, Hongtao Liu   +16 more
doaj   +1 more source

Selinexor combined with R-GDP as salvage therapy in relapsed/refractory diffuse large B-cell lymphoma. [PDF]

Am J Cancer Res
Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) remains a therapeutic challenge with poor prognosis. Selinexor, a selective inhibitor of nuclear export (XPO1), has shown activity in this setting. We retrospectively evaluated the efficacy
Jiang S, Li Y, Liu C, Liu Y, Zhang Q, Lv F, Zhang W.   +6 more
europepmc   +2 more sources

Case report: Safety and efficacy of synergistic treatment using selinexor and azacitidine in patients with atypical chronic myeloid leukemia with resistance to decitabine

Frontiers in Oncology
BackgroundAtypical chronic myeloid leukemia (aCML) is a BCR::ABL1 negative myelodysplastic/myeloproliferative neoplasm with poor overall survival.
Lu Liu, Xiaofeng Song, Wenhao Dong, Zhao Li, Dongmei Guo   +4 more
doaj   +1 more source

Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor

Current Oncology
Best practice (BP) in cancer care consists of a multifaceted approach comprising individualized treatment plans, evidence-based medicine, the optimal use of supportive care and patient education.
Lucio N. Gordan, David Ray, Stephen C. Ijioma, George Dranitsaris, Amanda Warner, Trevor Heritage, Matthew Fink, David Wenk, Paul Chadwick, Natasha Khrystolubova, Shachar Peles   +10 more
doaj   +1 more source

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial

Haematologica, 2018
Targeted therapies against FLT3-mutated acute myeloid leukemias have shown limited clinical efficacy primarily because of the acquisition of secondary mutations in FLT3 and persistent activation of downstream pro-survival pathways such as MEK/ERK, PI3K ...
Weiguo Zhang, Charlie Ly, Jo Ishizawa, Hong Mu, Vivian Ruvolo, Sharon Shacham, Naval Daver, Michael Andreeff   +7 more
doaj   +1 more source

The nuclear export inhibitor selinexor improves kidney function in a rat model of focal segmental glomerulosclerosis.

AJP - Renal Physiology
Focal segmental glomerulosclerosis (FSGS) is a common glomerular pathology characterized by podocyte injury, which can lead to kidney failure. Among the factors contributing to podocyte damage are mutations in nuclear pore complexes (NPCs), which ...
Ying-Ying Gao, Mohamed Hamed, I. V. Martin, U. Raffetseder, Xiyang Liu, A. Leitz, Marcus Moeller, E. Stamellou, Ramona Jühlen, Angela Schulz, R. Kreutz, J. Floege, R. Kramann, Wolfram Antonin, T. Ostendorf   +14 more
semanticscholar   +1 more source

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma

Oncotarget, 2016
Selinexor is an orally bioavailable selective inhibitor of nuclear export that has been demonstrated to have preclinical activity in various cancer types and that is currently in Phase I and II clinical trials for advanced cancers. In this study, we evaluated the effects of selinexor in several preclinical models of various sarcoma subtypes.
Nakayama, Robert, Sicinska, Ewa, Fletcher, Jonathan, Demetri, George, Wagner, Andrew, Zhang, Yi-Xiang, Czaplinski, Jeffrey T., Anatone, Alex J.   +7 more
openaire   +5 more sources

Incorporation of selinexor into conditioning regimens prior to allogeneic hematopoietic stem cell transplantation: a single-center clinical study

Hematology
Objective Clinical data on incorporating selinexor into conditioning regimens before allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain limited.
Bingjie Wang, Qian Wang, Jialin Zhu, Zeyin Liang, Yue Yin, Yuan Li, Jinping Ou, Hanyun Ren, Yujun Dong   +8 more
doaj   +1 more source

Selinexor Reduces the Immunosuppression of Macrophages and Synergizes With CD19 CAR‐T Cells Against B‐Cell Lymphoma

Cancer Science
CD19 chimeric antigen receptor (CAR)‐T cell therapy has achieved high response rates in patients with B‐cell lymphoma. However, treatment failure and relapse can be attributable to CAR‐T cell dysfunction and the immunosuppression of the tumor ...
W. Luo, Jia Xu, Cheng-Gong Li, Lu Tang, Ying-Ying Li, Xin-Di Wang, Zhuo-Lin Wu, Yin-Qiang Zhang, H. Mei, Yu Hu   +9 more
semanticscholar   +1 more source